<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Tumor Response Assessment Using Volumetric Doubling Time" /><meta property="og:locale" content="en" /><meta name="description" content="Imaging is commonly used to assess tumor response to novel therapies in oncology clinical trials. As a surrogate marker to predict the clinically relevant factors of time to progression or patient survival, physicians use the response evaluation criteria in solid tumors (RECIST) 1.1 criteria to measure tumors on computed tomography (CT) scans . RECIST 1.1 assesses changes in linear size of a subset of target lesions. Treatment decisions are based on whether these measurements indicate progressive or stable disease or partial or complete response. Based on these decisions, therapies either pass or fail the clinical trial, leading to either adoption or abandonment of the therapy." /><meta property="og:description" content="Imaging is commonly used to assess tumor response to novel therapies in oncology clinical trials. As a surrogate marker to predict the clinically relevant factors of time to progression or patient survival, physicians use the response evaluation criteria in solid tumors (RECIST) 1.1 criteria to measure tumors on computed tomography (CT) scans . RECIST 1.1 assesses changes in linear size of a subset of target lesions. Treatment decisions are based on whether these measurements indicate progressive or stable disease or partial or complete response. Based on these decisions, therapies either pass or fail the clinical trial, leading to either adoption or abandonment of the therapy." /><link rel="canonical" href="https://clinicaltree.github.io/posts/tumor-response-assessment-using-volumetric-doubling-time/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/tumor-response-assessment-using-volumetric-doubling-time/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2014-07-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Tumor Response Assessment Using Volumetric Doubling Time" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T02:43:55+00:00","datePublished":"2014-07-31T17:00:00+00:00","description":"Imaging is commonly used to assess tumor response to novel therapies in oncology clinical trials. As a surrogate marker to predict the clinically relevant factors of time to progression or patient survival, physicians use the response evaluation criteria in solid tumors (RECIST) 1.1 criteria to measure tumors on computed tomography (CT) scans . RECIST 1.1 assesses changes in linear size of a subset of target lesions. Treatment decisions are based on whether these measurements indicate progressive or stable disease or partial or complete response. Based on these decisions, therapies either pass or fail the clinical trial, leading to either adoption or abandonment of the therapy.","headline":"Tumor Response Assessment Using Volumetric Doubling Time","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/tumor-response-assessment-using-volumetric-doubling-time/"},"url":"https://clinicaltree.github.io/posts/tumor-response-assessment-using-volumetric-doubling-time/"}</script><title>Tumor Response Assessment Using Volumetric Doubling Time | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Tumor Response Assessment Using Volumetric Doubling Time</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Tumor Response Assessment Using Volumetric Doubling Time</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1406826000" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Jul 31, 2014 </em> </span> <span> Updated <em class="" data-ts="1681094635" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Ronald M. Summers MD PhD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="1092 words"> <em>6 min</em> read</span></div></div></div><div class="post-content"><p>Imaging is commonly used to assess tumor response to novel therapies in oncology clinical trials. As a surrogate marker to predict the clinically relevant factors of time to progression or patient survival, physicians use the response evaluation criteria in solid tumors (RECIST) 1.1 criteria to measure tumors on computed tomography (CT) scans . RECIST 1.1 assesses changes in linear size of a subset of target lesions. Treatment decisions are based on whether these measurements indicate progressive or stable disease or partial or complete response. Based on these decisions, therapies either pass or fail the clinical trial, leading to either adoption or abandonment of the therapy.</p><p>It is well recognized that the RECIST criteria have important limitations. Only a subset of lesions in a given patient are measured. Only a single linear measurement is obtained per lesion. For multiple lesions, the linear measurements of each are summed, compounding the errors and deficiencies inherent in each individual linear measurement. Bone disease is ignored. Large thresholds are used for assessing response or progression, with a 30% reduction in linear size required for response and a 20% minimum increase required for progression. Such large thresholds are meant to compensate for the variability in linear measurements. This variability is a consequence of the difficulty of measuring irregular tumor shapes and poor inter- and intra-observer measurement agreement.</p><p>A common sense solution to one of the deficiencies in the RECIST measurement method is to obtain volumetric assessment. A number of studies have been published demonstrating semiautomated and fully automated volumetric measurement techniques for different types of tumors . Although promising, these automated techniques are neither well established yet nor widely available.</p><p>In the article by Seyal at al. in this issue of <em>Academic Radiology</em> , the authors compare tumor growth kinetics with RECIST in a group of women with breast cancer liver metastases who have undergone treatment with yttrium-90 radioembolotherapy. Using a commercial semiautomated tumor volume measurement tool, the authors measured 34 liver metastases in 21 patients on pre-and post-treatment CT scans. From the volumetric measurements, they computed the reciprocal of the doubling time (RDT). RDT indicates the number of times a tumor doubles its volume in a year.</p><p>To distinguish true volume changes from those within measurement error, the authors computed an absolute percentage error from the volumes measured at two time points. Absolute percentage errors &lt;7.87% were attributed to measurement error, and therefore, the change was considered a stable disease. The 7.87% threshold was determined from a previously published phantom experiment using the same software used in this study . If the change in volume exceeded that expected because of measurement error, the change in volume was considered a true change. In that case, the RDT was assessed. If RDT was negative, the disease was considered a partial response (PR). If positive, the disease was considered a progressive disease (PD). If the lesion disappeared, the disease was considered a complete response.</p><p>In RECIST 1.1, multiple lesions are handled by summing the linear dimensions of all lesions (up to 5 per patient). In the article by Seyal et al. , a maximum of two well-defined lesions per treated hepatic lobe were selected for evaluation. Each lesion was assessed independently by RECIST 1.1 and RDT.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="acknowledgments"><span class="mr-2">Acknowledgments</span><a href="#acknowledgments" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Eisenhauer E.A., Therasse P., Bogaerts J., et. al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: pp. 228-247. (Oxford, England: 1990)</p><li><p>2. Lubner M.G., Dustin Pooler B., Del Rio A.M., et. al.: Volumetric evaluation of hepatic tumors: multi-vendor, multi-reader liver phantom study. Abdom Imaging 2014;</p><li><p>3. Awad J., Owrangi A., Villemaire L., et. al.: Three-dimensional lung tumor segmentation from x-ray computed tomography using sparse field active models. Med Phys 2012; 39: pp. 851-865.</p><li><p>4. Liu J., Wang S., Linguraru M.G., et. al.: A variational framework for joint detection and segmentation of ovarian cancer metastases. Med Image Comput Assist Interv 2013; 16: pp. 83-90.</p><li><p>5. Seyal A., Parekh K., Velichko Y., et. al.: Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases. Academic Radiology 2014; 21: pp. 950-957.</p><li><p>6. Keil S., Plumhans C., Behrendt F.F., et. al.: Semi-automated quantification of hepatic lesions in a phantom. Invest Radiol 2009; 44: pp. 82-88.</p><li><p>7. Stein W.D., Gulley J.L., Schlom J., et. al.: Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011; 17: pp. 907-917.</p><li><p>8. Stein W.D., Yang J., Bates S.E., et. al.: Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist 2008; 13: pp. 1055-1062.</p><li><p>9. Choi H., Charnsangavej C., Faria S.C., et. al.: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: pp. 1753-1759.</p><li><p>10. Tirkes T., Hollar M.A., Tann M., et. al.: Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics 2013; 33: pp. 1323-1341.</p><li><p>11. Miller A.B., Hoogstraten B., Staquet M., et. al.: Reporting results of cancer treatment. Cancer 1981; 47: pp. 207-214.</p><li><p>12. Wahl R.L., Jacene H., Kasamon Y., et. al.: From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50: pp. 122S-150S.</p><li><p>13. Lencioni R., Llovet J.M.: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: pp. 52-60.</p><li><p>14. Smith A.D., Shah S.N., Rini B.I., et. al.: Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010; 194: pp. 1470-1478.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-21/'>Volume 21</a>, <a href='/categories/issue-8/'>Issue 8</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Tumor%20Response%20Assessment%20Using%20Volumetric%20Doubling%20Time%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Ftumor-response-assessment-using-volumetric-doubling-time%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Tumor%20Response%20Assessment%20Using%20Volumetric%20Doubling%20Time%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Ftumor-response-assessment-using-volumetric-doubling-time%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Ftumor-response-assessment-using-volumetric-doubling-time%2F&text=Tumor%20Response%20Assessment%20Using%20Volumetric%20Doubling%20Time%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/a-multiobserver-study-of-the-effects-of-including-point-of-care-patient-photographs-with-portable-ra/"><div class="card-body"> <em class="small" data-ts="1406826000" data-df="ll" > Jul 31, 2014 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>A Multiobserver Study of the Effects of Including Point-of-care Patient Photographs with Portable Radiography</h3><div class="text-muted small"><p> Rationale and Objectives To evaluate whether the presence of facial photographs obtained at the point-of-care of portable radiography leads to increased detection of wrong-patient errors. Materia...</p></div></div></a></div><div class="card"> <a href="/posts/a-workflow-to-improve-the-alignment-of-prostate-imaging-with-whole-mount-histopathology/"><div class="card-body"> <em class="small" data-ts="1406826000" data-df="ll" > Jul 31, 2014 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>A Workflow to Improve the Alignment of Prostate Imaging with Whole-mount Histopathology</h3><div class="text-muted small"><p> Rationale and Objectives Evaluation of prostate imaging tests against whole-mount histology specimens requires accurate alignment between radiologic and histologic data sets. Misalignment results ...</p></div></div></a></div><div class="card"> <a href="/posts/automated-percentage-of-breast-density-measurements-for-full-field-digital-mammography-applications/"><div class="card-body"> <em class="small" data-ts="1406826000" data-df="ll" > Jul 31, 2014 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Automated Percentage of Breast Density Measurements for Full-field Digital Mammography Applications</h3><div class="text-muted small"><p> Rationale and Objectives Increased mammographic breast density is a significant risk factor for breast cancer. A reproducible, accurate, and automated breast density measurement is required for fu...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/tumor-growth-kinetics-versus-recist-to-assess-response-to-locoregional-therapy-in-breast-cancer-live/" class="btn btn-outline-primary" prompt="Older"><p>Tumor Growth Kinetics Versus RECIST to Assess Response to Locoregional Therapy in Breast Cancer Liver Metastases</p></a> <a href="/posts/work-and-retirement-preferences-of-practicing-radiologists-as-a-predictor-of-workforce-needs/" class="btn btn-outline-primary" prompt="Newer"><p>Work and Retirement Preferences of Practicing Radiologists as a Predictor of Workforce Needs</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
